NEW YORK and MELBOURNE, Australia, Dec. 3, 2013 -- Regenerative medicine company Mesoblast Limited today announced top-line results from the Phase 2 trial of its proprietary Mesenchymal Precursor Cells in subjects with type 2 diabetes.
http://www.globenewswire.com/news-release/2013/12/04/594336/10060312/en/Mesoblast-Reports-Positive-Type-2-Diabetes-Trial-Results.html
http://www.globenewswire.com/news-release/2013/12/04/594336/10060312/en/Mesoblast-Reports-Positive-Type-2-Diabetes-Trial-Results.html
No comments:
Post a Comment